Submission + - Apple Watch is Cleared by the CBP of Infringing on the ECG Patent (cbp.gov)
We find that Apple Inc. (“Apple”) has met its burden to show that certain redesigned wearable devices (“articles at issue”) do not infringe one or more of claims 12, 13, and 19-23 of U.S. Patent No. 10,638,941 (“the ’941 Patent”) and claims 1, 3, 5, 8-10, 12, 15, and 16 of U.S. Patent No. 10,595,731 (“the ’731 Patent). Thus, CBP’s position is that the articles at issue are not subject to the limited exclusion order that the U.S. International Trade Commission (“Commission” or “ITC”) issued in Investigation No. 337-TA-1266 (“the underlying investigation” or “the 1266 investigation”), pursuant to Section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 (“Section 337”).